Evidence map›Paper›PMID 36911939›Full record

ArticleJournal of Alzheimer's disease : JAD2023

Assessing the Role of Past Depression in Patients with Mild Cognitive Impairment, with and without Biomarkers for Alzheimer's Disease.

Angela C Golas, Patrick Salwierz, Tarek K Rajji, Christopher R Bowie, Meryl A Butters, Corinne E Fischer, Alastair J Flint, Nathan Herrmann, Linda Mah, Benoit H Mulsant and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Angela C GolasCentre for Addiction and Mental Health, Toronto, ON, Canada.
Patrick SalwierzCentre for Addiction and Mental Health, Toronto, ON, Canada.
Tarek K RajjiCentre for Addiction and Mental Health, Toronto, ON, Canada.
Christopher R BowieCentre for Addiction and Mental Health, Toronto, ON, Canada.
Meryl A ButtersDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
Corinne E FischerDepartment of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Alastair J FlintDepartment of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Nathan HerrmannDepartment of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Linda MahDepartment of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Benoit H MulsantCentre for Addiction and Mental Health, Toronto, ON, Canada.
Bruce G PollockCentre for Addiction and Mental Health, Toronto, ON, Canada.
Foad TaghdiriTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
Wei WangCentre for Addiction and Mental Health, Toronto, ON, Canada.
M Carmela TartagliaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
PACt-MD Study Group
Centre for Addiction and Mental Health · CASt. Michael's Hospital · CASunnybrook Health Science Centre · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Major depressive disorder (MDD) is a risk factor for Alzheimer's disease (AD). Cerebrovascular disease (CVD) is implicated in MDD and AD. Our study compared participants with AD positive and negative cerebrospinal fluid (CSF) biomarkers on neuropsychological performance, remitted MDD status, and CVD burden. Next, we compared AD-CSF biomarkers and white matter hyperintensities (WMH) burden among three groups: mild cognitive impairment (MCI) (n = 12), MCI with remitted MDD (MDD+MCI) (n = 12), and remitted MDD alone (MDD) (n = 7). Few participants (18%) with MCI+MDD exhibited AD(+) biomarkers. Nearly all participants had moderate-severe WMH. WMH may contribute to cognitive impairment or depression in MCI patients with AD(-) biomarkers.

Indexed as

Alzheimer DiseaseCardiovascular DiseasesCognitive DysfunctionMajor Depressive DisorderAmyloid beta-PeptidesBiomarkersDepressionHumansNeuropsychological Teststau ProteinsAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer’s diseasecerebrovascular diseasemajor depressive disordermild neurocognitive disorder

Identifiers

PMID36911939
PMCPMC10200207
OpenAlexW4323832854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.